Laboratoire des Sciences Analytiques-UMR CNRS 5180, Université de Lyon, Université Claude Bernard-Lyon 1, Bât. ESCPE Lyon, Domaine scientifique de la Doua, 69622 Villeurbanne cedex, France.
Curr Opin Chem Biol. 2011 Aug;15(4):469-74. doi: 10.1016/j.cbpa.2011.02.020. Epub 2011 Mar 14.
Fragment-based screening has now become an established method for the generation of lead molecules against therapeutic targets. Fragment molecules are simple, low molecular-weight compounds with few chemical functionalities. These characteristics lead to high hit rates for fragment screening as compared to the more classical High-Throughput Screening of drug-like molecules and raise the question of the specificity of fragment molecules. This review analyzes recent outcomes of fragment screenings published in the literature, showing that the specificity of the fragments can be related to their structures and physico-chemical properties. We also discuss both the concept of privileged fragment scaffolds and the role of fragment-based screening in predicting protein druggability, highlighted by recent publications in the field.
基于片段的筛选现已成为针对治疗靶标生成先导分子的一种成熟方法。片段分子是具有较少化学官能团的简单、低分子量化合物。与更经典的药物样分子高通量筛选相比,这些特性导致片段筛选的命中率较高,并引发了片段分子特异性的问题。本文综述了文献中发表的片段筛选的最新结果,表明片段的特异性可以与其结构和物理化学性质相关。我们还讨论了片段的优势骨架的概念以及片段筛选在预测蛋白质成药性方面的作用,这一点被该领域的最新出版物所强调。